Humacyte Correlations
| HUMA Stock | USD 1.14 0.13 12.87% |
The current 90-days correlation between Humacyte and Entrada Therapeutics is 0.27 (i.e., Modest diversification). The correlation of Humacyte is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Humacyte Correlation With Market
Excellent diversification
The correlation between Humacyte and DJI is -0.52 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Humacyte and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Humacyte Stock
| 0.65 | VCYT | Veracyte Earnings Call This Week | PairCorr |
| 0.65 | DRMA | Dermata Therapeutics | PairCorr |
| 0.74 | DTIL | Precision BioSciences | PairCorr |
Moving against Humacyte Stock
| 0.73 | EQ | Equillium | PairCorr |
| 0.64 | DRTS | Alpha Tau Medical | PairCorr |
| 0.62 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.56 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.48 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.46 | DSGN | Design Therapeutics | PairCorr |
| 0.44 | VERA | Vera Therapeutics | PairCorr |
| 0.4 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.39 | CMB | Cambium Bio Earnings Call This Week | PairCorr |
| 0.31 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.68 | VNDA | Vanda Pharmaceuticals | PairCorr |
| 0.66 | 0P6S | Bayer AG NA Earnings Call This Week | PairCorr |
| 0.6 | DVAX | Dynavax Technologies Earnings Call Tomorrow | PairCorr |
| 0.58 | SRZNW | Surrozen Warrant | PairCorr |
| 0.57 | VRTX | Vertex Pharmaceuticals | PairCorr |
| 0.54 | VTVT | vTv Therapeutics | PairCorr |
| 0.51 | S09 | Sutro Biopharma Split | PairCorr |
| 0.48 | HDP1 | Arrowhead Pharmaceuticals | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Humacyte Stock performing well and Humacyte Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Humacyte's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| TRDA | 2.81 | 0.57 | 0.18 | 0.98 | 2.72 | 6.65 | 18.48 | |||
| ARCT | 2.91 | (0.28) | 0.00 | (0.07) | 0.00 | 6.53 | 15.98 | |||
| ACHV | 3.10 | (0.21) | 0.00 | (0.04) | 0.00 | 5.86 | 25.05 | |||
| VYGR | 2.47 | (0.35) | 0.00 | (0.22) | 0.00 | 4.58 | 19.71 | |||
| SGMT | 3.27 | (0.72) | 0.00 | (0.51) | 0.00 | 5.78 | 22.02 | |||
| IMRX | 3.89 | (0.12) | 0.00 | (0.74) | 0.00 | 8.98 | 67.18 | |||
| VNDA | 3.98 | 0.70 | 0.12 | 7.20 | 4.87 | 11.39 | 43.09 | |||
| FHTX | 3.62 | 0.38 | 0.11 | 0.29 | 3.34 | 8.60 | 31.12 | |||
| AVIR | 2.51 | 0.49 | 0.13 | 0.69 | 3.04 | 7.21 | 17.79 | |||
| NAUT | 4.56 | 0.93 | 0.17 | (2.57) | 4.34 | 9.85 | 28.35 |
Humacyte Corporate Management
| Harold Alterson | Senior Quality | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Dale Sander | Chief CFO | Profile | |
| Heather Connelly | Senior Quality | Profile | |
| William Scheessele | Chief Officer | Profile | |
| Yang MD | Chief Officer | Profile |